|
1
|
Gandhi NM, Morales A and Lamm DL: Bacillus
Calmette-Guérin immunotherapy for genitourinary cancer. BJU Int.
112:288–297. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hall MC, Chang SS, Dalbagni G, Pruthi RS,
Seigne JD, Skinner EC, Wolf JS Jr and Schellhammer PF: Guideline
for the management of nonmuscle invasive bladder cancer (stages Ta,
T1, and Tis): 2007 update. J Urol. 178:2314–2330. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alexandroff AB, Nicholson S, Patel PM and
Jackson AM: Recent advances in bacillus Calmette-Guerin
immunotherapy in bladder cancer. Immunotherapy. 2:551–560. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Haley JL, Young DG, Alexandroff A, James K
and Jackson AM: Enhancing the immunotherapeutic potential of
mycobacteria by transfection with tumour necrosis factor-alpha.
Immunology. 96:114–121. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ratliff TL, Kavoussi LR and Catalona WJ:
Role of fibronectin in intravesical BCG therapy for superficial
bladder cancer. J Urol. 139:410–414. 1988.PubMed/NCBI
|
|
6
|
Kresowik TP and Griffith TS: Bacillus
Calmette-Guerin immunotherapy for urothelial carcinoma of the
bladder. Immunotherapy. 1:281–288. 2009. View Article : Google Scholar :
|
|
7
|
Bevers RF, Kurth KH and Schamhart DH: Role
of urothelial cells in BCG immunotherapy for superficial bladder
cancer. Br J Cancer. 91:607–612. 2004.PubMed/NCBI
|
|
8
|
Williams SK, Hoenig DM, Ghavamian R and
Soloway M: Intravesical therapy for bladder cancer. Expert Opin
Pharmacother. 11:947–958. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Delimpoura V, Samitas K, Vamvakaris I,
Zervas E and Gaga M: Concurrent granulomatous hepatitis,
pneumonitis and sepsis as a complication of intravesical BCG
immunotherapy. BMJ Case Rep. 10:20132013.
|
|
10
|
Kawai K, Miyazaki J, Joraku A, Nishiyama H
and Akaza H: Bacillus Calmette-Guerin (BCG) immunotherapy for
bladder cancer: Current understanding and perspectives on
engineered BCG vaccine. Cancer Sci. 104:22–27. 2013. View Article : Google Scholar
|
|
11
|
Joudi FN, Smith BJ and O’Donnell MA;
National BCG-Interferon Phase 2 Investigator Group: Final results
from a national multicenter phase II trial of combination bacillus
Calmette-Guérin plus interferon alpha-2B for reducing recurrence of
superficial bladder cancer. Urol Oncol. 24:344–348. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nepple KG, Lightfoot AJ, Rosevear HM,
O’Donnell MA and Lamm DL; Bladder Cancer Genitourinary Oncology
Study Group: Bacillus Calmette-Guérin with or without interferon
α-2b and megadose versus recommended daily allowance vitamins
during induction and maintenance intravesical treatment of
nonmuscle invasive bladder cancer. J Urol. 184:1915–1919. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lam JS, Benson MC, O’Donnell MA, Sawczuk
A, Gavazzi A, Wechsler MH and Sawczuk IS: Bacillus Calmete-Guérin
plus interferon-alpha2B intravesical therapy maintains an extended
treatment plan for superficial bladder cancer with minimal
toxicity. Urol Oncol. 21:354–360. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bazarbashi S, Soudy H, Abdelsalam M,
Al-Jubran A, Akhtar S, Memon M, Aslam M, Kattan S and Shoukri M:
Co-administration of intravesical bacillus Calmette-Guérin and
interferon α-2B as first line in treating superficial transitional
cell carcinoma of the urinary bladder. BJU Int. 108:1115–1118.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Askeland EJ, Newton MR, O’Donnell MA and
Luo Y: Bladder cancer immunotherapy: BCG and beyond. Adv Urol.
2012:1819872012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chapman R, Chege G, Shephard E, Stutz H
and Williamson AL: Recombinant Mycobacterium bovis BCG as an HIV
vaccine vector. Curr HIV Res. 8:282–298. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun E, Nian X, Liu C, Fan X and Han R:
Construction of recombinant human IFNa-2b BCG and its antitumor
effects on bladder cancer cells in vitro. Genet Mol Res.
14:3436–3449. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mugabe C, Raven PA, Fazli L, Baker JH,
Jackson JK, Liggins RT, So AI, Gleave ME, Minchinton AI, Brooks DE,
et al: Tissue uptake of docetaxel loaded hydrophobically
derivatized hyper-branched polyglycerols and their effects on the
morphology of the bladder urothelium. Biomaterials. 33:692–703.
2012. View Article : Google Scholar
|
|
19
|
Luo Y, Chen X and O’donnell MA: Use of
prostate specific antigen to measure bladder tumor growth in a
mouse orthotopic model. J Urol. 172:2414–2420. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bayne LJ and Vonderheide RH:
Immunohistochemical assessment of immune cells in mouse tumor
tissue. Cold Spring Harb Protoc. 2013:843–848. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ohuchida K, Mizumoto K, Ishikawa N, Fujii
K, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M and Tanaka M: The
role of S100A6 in pancreatic cancer development and its clinical
implication as a diagnostic marker and therapeutic target. Clin
Cancer Res. 11:7785–7793. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Saban MR, Simpson C, Davis C, Wallis G,
Knowlton N, Frank MB, Centola M, Gallucci RM and Saban R:
Discriminators of mouse bladder response to intravesical Bacillus
Calmette-Guerin (BCG). BMC Immunol. 8:62007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yanase N, Hayashida M, Kanetaka-Naka Y,
Hoshika A and Mizuguchi J: PKC-δ mediates interferon-α-induced
apoptosis through c-Jun NH2-terminal kinase activation.
BMC Cell Biol. 13:72012. View Article : Google Scholar
|
|
24
|
Yanase N, Kanetaka Y and Mizuguchi J:
Interferon-α-induced apoptosis via tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL)-dependent and -independent
manner. Oncol Rep. 18:1031–1038. 2007.PubMed/NCBI
|
|
25
|
Chen F, Zhang G, Iwamoto Y and See WA:
Bacillus Calmette-Guerin initiates intracellular signaling in a
transitional carcinoma cell line by cross-linking alpha 5 beta 1
integrin. J Urol. 170:605–610. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Villeneuve C, Gilleron M,
Maridonneau-Parini I, Daffé M, Astarie-Dequeker C and Etienne G:
Mycobacteria use their surface-exposed glycolipids to infect human
macrophages through a receptor-dependent process. J Lipid Res.
46:475–483. 2005. View Article : Google Scholar
|
|
27
|
Moriwaki Y, Begum NA, Kobayashi M,
Matsumoto M, Toyoshima K and Seya T: Mycobacterium bovis Bacillus
Calmette-Guerin and its cell wall complex induce a novel lysosomal
membrane protein, SIMPLE, that bridges the missing link between
lipopolysaccharide and p53-inducible gene, LITAF(PIG7), and
estrogen-inducible gene, EET-1. J Biol Chem. 276:23065–23076. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kato T, Bilim V, Yuuki K, Naito S,
Yamanobe T, Nagaoka A, Yano I, Akaza H and Tomita Y: Bacillus
Calmette-Guerin and BCG cell wall skeleton suppressed viability of
bladder cancer cells in vitro. Anticancer Res. 30:4089–4096.
2010.PubMed/NCBI
|
|
29
|
Ishibashi T, Yamada H, Harada S, Harada Y,
Takamoto M and Sugiyama K: Comparison of the mode of
immunopotentiating action of BCG and wax D. II. Effect on the
methylcholanthrene carcinogenesis. Jpn J Exp Med. 47:435–440.
1977.PubMed/NCBI
|
|
30
|
Kato M: Action of a toxic glycolipid of
Corynebacterium diph-theriae on mitochondrial structure and
function. J Bacteriol. 101:709–716. 1970.PubMed/NCBI
|
|
31
|
Fujita Y, Okamoto Y, Uenishi Y, Sunagawa
M, Uchiyama T and Yano I: Molecular and supra-molecular structure
related differences in toxicity and granulomatogenic activity of
mycobacterial cord factor in mice. Microb Pathog. 43:10–21. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ryll R, Watanabe K, Fujiwara N, Takimoto
H, Hasunuma R, Kumazawa Y, Okada M and Yano I: Mycobacterial cord
factor, but not sulfolipid, causes depletion of NKT cells and
upregulation of CD1d1 on murine macrophages. Microbes Infect.
3:611–619. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hamasaki N, Isowa K, Kamada K, Terano Y,
Matsumoto T, Arakawa T, Kobayashi K and Yano I: In vivo
administration of mycobacterial cord factor (Trehalose
6,6′-dimycolate) can induce lung and liver granulomas and thymic
atrophy in rabbits. Infect Immun. 68:3704–3709. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Saban MR, Hellmich HL, Simpson C, Davis
CA, Lang ML, Ihnat MA, O’Donnell MA, Wu XR and Saban R: Repeated
BCG treatment of mouse bladder selectively stimulates small GTPases
and HLA antigens and inhibits single-spanning uroplakins. BMC
Cancer. 7:2042007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Miyazaki J, Kawai K, Kojima T, Oikawa T,
Joraku A, Shimazui T, Nakaya A, Yano I, Nakamura T, Harashima H, et
al: The lipo-some-incorporating cell wall skeleton of Mycobacterium
bovis bacillus Calmette-Guéin can directly enhance the
susceptibility of cancer cells to lymphokine-activated killer cells
through up-regulation of natural-killer group 2, member D ligands.
BJU Int. 108:1520–1526. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen FH, Crist SA, Zhang GJ, Iwamoto Y and
See WA: Interleukin-6 production by human bladder tumor cell lines
is up-regulated by bacillus Calmette-Guérin through nuclear
factor-kappaB and Ap-1 via an immediate early pathway. J Urol.
168:786–797. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang G, Chen F, Cao Y and See WA:
Bacillus Calmette-Guérin induces p21 expression in human
transitional carcinoma cell lines via an immediate early, p53
independent pathway. Urol Oncol. 25:221–227. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
He C, Jiang H, Geng S, Sheng H, Shen X,
Zhang X, Zhu S, Chen X, Yang C and Gao H: Expression and prognostic
value of c-Myc and Fas (CD95/APO1) in patients with pancreatic
cancer. Int J Clin Exp Pathol. 7:742–750. 2014.PubMed/NCBI
|
|
39
|
Belardelli F and Ferrantini M: Cytokines
as a link between innate and adaptive antitumor immunity. Trends
Immunol. 23:201–208. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Elsäßer J, Janssen MW, Becker F, Suttmann
H, Schmitt K, Sester U, Stöckle M and Sester M: Antigen-specific
CD4 T cells are induced after intravesical BCG-instillation therapy
in patients with bladder cancer and show similar cytokine profiles
as in active tuberculosis. PLoS One. 8:e698922013. View Article : Google Scholar
|
|
41
|
Ingersoll MA and Albert ML: From infection
to immunotherapy: Host immune responses to bacteria at the bladder
mucosa. Mucosal Immunol. 6:1041–1053. 2013.PubMed/NCBI
|
|
42
|
Monjazeb AM, Hsiao HH, Sckisel GD and
Murphy WJ: The role of antigen-specific and non-specific
immunotherapy in the treatment of cancer. J Immunotoxicol.
9:248–258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shankaran V, Ikeda H, Bruce AT, White JM,
Swanson PE, Old LJ and Schreiber RD: IFNgamma and lymphocytes
prevent primary tumour development and shape tumour immunogenicity.
Nature. 410:1107–1111. 2001. View Article : Google Scholar
|
|
44
|
D’Orazio SE, Halme DG, Ploegh HL and
Starnbach MN: Class Ia MHC-deficient BALB/c mice generate
CD8+ T cell-mediated protective immunity against
Listeria monocytogenes infection. J Immunol. 171:291–298. 2003.
View Article : Google Scholar
|
|
45
|
Kamat AM and Lamm DL: Immunotherapy for
bladder cancer. Curr Urol Rep. 2:62–69. 2001. View Article : Google Scholar
|
|
46
|
Satyam A, Singh P, Badjatia N, Seth A and
Sharma A: A disproportion of TH1/TH2 cytokines with predominance of
TH2, in urothelial carcinoma of bladder. Urol Oncol. 29:58–65.
2011. View Article : Google Scholar
|
|
47
|
Abadie V, Badell E, Douillard P,
Ensergueix D, Leenen PJ, Tanguy M, Fiette L, Saeland S, Gicquel B
and Winter N: Neutrophils rapidly migrate via lymphatics after
Mycobacterium bovis BCG intradermal vaccination and shuttle live
bacilli to the draining lymph nodes. Blood. 106:1843–1850. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Luo Y, Chen X, Downs TM, DeWolf WC and
O’Donnell MA: IFN-alpha 2B enhances Th1 cytokine responses in
bladder cancer patients receiving Mycobacterium bovis bacillus
Calmette-Guérin immunotherapy. J Immunol. 162:2399–2405.
1999.PubMed/NCBI
|
|
49
|
Böhle A and Brandau S: Immune mechanisms
in bacillus Calmette-Guerin immunotherapy for superficial bladder
cancer. J Urol. 170:964–969. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Luo Y, Chen X and O’Donnell MA: Role of
Th1 and Th2 cytokines in BCG-induced IFN-gamma production: Cytokine
promotion and simulation of BCG effect. Cytokine. 21:17–26. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Panaretakis T, Pokrovskaja K, Shoshan MC
and Grandér D: Interferon-alpha-induced apoptosis in U266 cells is
associated with activation of the proapoptotic Bcl-2 family members
Bak and Bax. Oncogene. 22:4543–4556. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Manna SK, Mukhopadhyay A and Aggarwal BB:
IFN-alpha suppresses activation of nuclear transcription factors
NF-kappa B and activator protein 1 and potentiates TNF-induced
apoptosis. J Immunol. 165:4927–4934. 2000. View Article : Google Scholar : PubMed/NCBI
|
